NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Gebo KA, Jenckes MW, Chander G, et al. Management of Chronic Hepatitis C. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 Jul. (Evidence Reports/Technology Assessments, No. 60.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Management of Chronic Hepatitis C

Management of Chronic Hepatitis C.

Show details

Acronyms and Abbreviations

AbbreviationTerm
^to the power of
+ANAantinuclear antibody
IV-C7S7S type IV collagen
A1mild inflammation
A2moderate inflammation
A3marked inflammation
abnlabnormal
AFPalpha fetoprotein
Albalbumin
ALTalanine aminotransferase
AMAagainst medical advice
ASMAantismooth muscle antibody
ASTaspartate aminotransferase
beta-NAGN-acetyl-beta-glucosaminidase
bidtwice a day
Bilibilirubin
bxbiopsy
CAcarbohydrate antigen
CAHchronic active hepatitis
CCcase control
CD4CD4 count (cell type)
CEAcarcoembryonic antigen
CHCchronic hepatitis C
CIconfidence interval
CohPcohort prospective
CohRcohort retrospective
CPHchronic persistent hepatitis
Crcreatinine
CScase series
CSAcyclosporine
CTcomputerized tomography
Dday(s)
DMdiabetes mellitus
DesDesmet
Disc/withdrdiscontinued treatments or withdrew from study
Dose reddose reduction
dxdiagnosis
elelevated
ELISAenzyme-linked immunosorbent assay
ETRend of treatment response
f/ufollow-up
Ggrade
ggram(s)
GGTgamma glutamyl transpeptidase
HAhyaluronic acid
HbsAghepatitis B surface antigen
HAIhistological activity index
HBVhepatitis B virus
HCChepatocellular carcinoma
HCVhepatitis C virus
Hgbhemoglobin
hrhour(s)
IDUintravenous drug user
IFNinterferon
Igimmunoglobulin
ILinterleukin
ISHIshak
ITTintention to treat
IVintravenous
KnoKnodell
Lliter(s)
LDHlactate dehydrogenase
LLlower limit
Ly IFN alphalymphoid interferon
MRImagnetic resonance imaging
minminute(s)
MetMetavir
mLmilliliter(s)
MMPmatrix metalloproteinase
Mn-SODmanganese superoxide dismutase
mo(s)month(s)
MRImagnetic resonance imaging
MUmillion units
n/snot specified
NASHnonalcoholic steatohepatitis
ngnanograms
nlnormal
NPn-terminal polypeptide
NRnot reported
NSnot significant
OCPsoral contraceptives
OLTorthotopic liver transplant
PCHEpseudocholinesterase
PCRpolymerase chain reaction
peg-IFNpegylated interferon
P-III-PProcollagen type III peptides
ptspatients
pltsplatelets
PTprothrombin time
PTTpartial thromboplastin time
qdonce a day
r IFNrecombinant IFN
r/orule out
RBVribavirin
RCTrandomized controlled trial
Sstaging
S0no fibrosis
S1, S2mild (portal) fibrosis
S3moderate (bridging) fibrosis
S4severe fibrosis (cirrhosis)
SBRsustained biochemical response
secsecond(s)
SchScheuer
SRsustained response
SVRsustained virological response
tidthree times a day
TIMPtissue inhibitor of metalloproteinase
tiwthree times a week
txtreatment
U/Sultrasound
ugmicrograms
ULupper limit
w/with
w/Iwithin
w/owithout
WBCwhite blood cell
WHOWorld Health Organization
wkweek(s)
XScross-sectional
yr(s)year(s)

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...